Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03359460 · ClinicalTrials.gov registry record · Phase 1
Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome
A Phase 1 study, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT03359460 is a Phase 1 study that has completed, run by University of California, Davis. The registered enrollment target is 4 participants.
The verdict
NCT03359460, a Phase 1 study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of ibrutinib when giving together with lenalidomide in treating patients with myelodysplastic syndrome. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib and lenalidomide may work better in treating patients with myelodysplastic syndrome.
Interventions
- DRUG Lenalidomide
- DRUG Ibrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2019-11-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03359460
The ClinicalTrials.gov registry entry for NCT03359460 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lenalidomide is the first listed.
NCT03359460 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03359460 about?
NCT03359460 is a clinical study titled "Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome". This phase I trial studies the side effects and best dose of ibrutinib when giving together with lenalidomide in treating patients with myelodysplastic syndrome. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as ...
What is the current status of trial NCT03359460?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2017-12-01. Estimated completion is 2019-11-17.
What interventions are being tested in trial NCT03359460?
The interventions under investigation include: Lenalidomide (DRUG), Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT03359460?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.